SVRA News
Notable Thursday Option Activity: SVRA, CAR, SPCX
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Savara Inc (Symbol: SVRA), where a total of 10,285 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 70.6% of...
Nasdaq News: Markets
Notable Thursday Option Activity: SVRA, CAR, SPCX
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Savara Inc (Symbol: SVRA), where a total of 10,285 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 70.6% of...
Nasdaq News: Markets
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9...
Business Wire
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new...
Business Wire
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2026 and provided a business update. While we have regulatory applications under review across the U.S., EU...
Business Wire
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human...
Business Wire
Here's Why You Should Add Savara Stock to Your Portfolio Now
SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.
Zacks
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline...
Yahoo! Finance: News
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new...
Business Wire
Savara Announces Chief Financial and Administrative Officer Transition
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of...
Business Wire
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on...
Business Wire